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ABSTRACT
The prevalence of various psychiatric disorders in people with epilepsy is high, with psychoses affecting 2–9% of patients. 
Antipsychotic drugs have been identified as increasing the risk of epileptic seizures. For first-generation antipsychotics such 
a risk appears to be relatively low, with the exception of chlorpromazine. Among second-generation antipsychotics, clozapine 
use carries the highest risk of seizure induction, while risperidone, quetiapine, amisulpride, and aripiprazole seem to pose 
a significantly lower risk. The incidence of an increased number of seizures is linked to the elevated blood plasma level effect of 
antipsychotics. To diminish the risk of seizures, it is important to start with a small dose of antipsychotic drug, to titrate slowly, 
to monitor serum levels of prescribed drugs, and to keep the drug at the minimal effective dose.
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Introduction
Psychiatric comorbidity is common in people with epilepsy, 
with 11-62% prevalence of mood disorders, and psychoses affec-
ting 2–9% of patients. Furthermore, psychotic disorders for which 
antipsychotic drugs may be prescribed are more common among 
people with epilepsy than in the general population [1, 2, 3, 4, 5]. 
Psychoses in people with epilepsy are categorised as peri-ictal 
or interictal psychoses. Peri-ictal psychoses can be divided into 
pre-ictal, ictal, and postictal. Interictal psychoses occur without 
a time relation with epileptic seizures [6]. It is worth noting that in-
terictal psychoses most commonly occur in temporal epilepsy [7]. 
 Almost all first- and second-generation antipsychotics 
are implicated in increasing the risk of epileptic seizures [8, 
9]. Electroencephalography (EEG) can be used to monitor 
patients suspected of seizures. EEG alterations without clinical 
repercussions are found in about 7% of antipsychotic drug users 
without a diagnosis of epilepsy, and 0.5–1.2% of them exhibited 
seizures [5].
Mechanism of psychosis in epilepsy
Dopaminergic activity is proven to have an impact on 
the development of psychosis, with dopamine antagonism 
being pro-convulsive and antipsychotic. The clinical efficacy 
of antipsychotic drugs is heavily correlated with their ability 
to block subcortical dopamine D2 receptors [10]. Focusing 
on epileptogenesis, there is recent evidence from both animal 
and human studies supporting the role of D1 and D2 recep-
tor signalling in limbic epilepsy. These studies point out that 
increased D1 receptor and decreased D2 receptor function 
might be involved in limbic epilepsy [11]. Bozzi and Borrelli 
have proposed that altered D1R and D2R signalling might con-
tribute to epileptogenesis through the activation of neuronal 
cell death cascades, activated by the protein kinase A (PKA)/ 
/extracellular-regulated kinase (ERK) and mammalian target 
of rapamycin (mTOR) pathways [11].
Antiepileptic drugs have been reported to have an impact 
on increasing the risk of psychosis. However the risk is small, 
with reported prevalences of 2.5% for vigabatrin, 1.9–2.3% for 
zonisamide, 0.8% for topiramate, 0.3–0.7% for levetiracetam, 
and 0.5% for gabapentin [12].
Antipsychotic drugs
First-generation antipsychotics
Chlorpromazine is thought to be particularly associated 
with a higher risk of provoking epileptic seizures. In a more 
than four-year long observational study by Logothetis et al. 
[13], all nonepileptic patients treated with first-generation 
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antipsychotic drugs were studied for spontaneous seizures. 
1.2% of 859 patients treated with phenothiazines experienced 
seizures, while no seizures occurred in the 669 patients with 
treatment other than phenothiazines. Two factors increasing 
the probability for seizures were found: the application of high 
dosages, and the time span around the initiation or escalation 
of the phenothiazine dose. Seizures occurred in 9% of the pa-
tients treated with high doses of first-generation antipsychotic 
drugs (1,000 mg/day chlorpromazine equivalent), in 0.7% of 
the patients with moderate doses, and in 0.3% of the patients 
with low doses (200 mg/day chlorpromazine equivalent) [13]. 
The piperazine phenothiazines (acetophenazine, fluphenazi-
ne, perphenazine, prochlorperazine and trifluoperazine) exhibit 
epileptogenic activity of less potential, while the lowest epileptoge-
nic effect among first-generation antipsychotic drugs has been 
observed with piperidine phenothiazines (e.g. thioridazine) and 
butyrophenones (e.g. haloperidol) [8, 14, 15]. Haloperidol has 
been proven not to decrease the epileptic threshold signifi-
cantly, which is why it should be considered in the treatment 
of acute and chronic psychoses in people with epilepsy [8, 
16, 17, 18]. The high affinity with D2 dopaminergic receptors 
presented by haloperidol results in antipsychotic action at 
low doses, which reduces the risk of seizures [14]. The only 
antipsychotic drug presenting no reported seizure risk, and 
in addition having a possible seizure-protective capability, is 
melperone (a drug not currently available in Poland). This is 
a sedative butyrophenone of low potency [19]. 
Second-generation antipsychotics
Clinical registries reveal a seizure incidence of 0.3–0.9% 
for most second-generation antipsychotic drugs [14]. Risperi-
done, olanzapine and quetiapine appear to be safe compared to 
chlorpromazine in terms of seizures. The anticonvulsive effect 
of dopamine is broadly known. Drugs selective for mesolimbic 
dopamine receptors, e.g. clozapine, olanzapine and quetiapine, 
exhibit more intense proconvulsive effects than drugs with low 
affinity to D2 receptor such as risperidone [20, 21]. Olanzapine 
and quetiapine have demonstrated seizure rates of 0.9% while 
risperidone has presented even lower rates (~0.3%) [22, 23]. 
Another study of 15 patients did not show an increase 
in seizures, even in cases of risperidone overdose [24]. In 
different studies, olanzapine has exhibited occurrence of sei-
zures in 0.24% [25], while in patients treated with quetiapine 
and a placebo no increase in seizure incidence was observed 
(0.4% and 0.5% respectively) [26]. The use of aripiprazole (the 
partial agonist of dopamine receptor) has been associated 
with a seizure rate of 0.1% in patients treated in short-term, 
premarketing placebo-controlled trials [8, 27]. In a study 
by Bloechliger et al. [28], aripiprazole and risperidone were 
among the second-generation antipsychotic drugs with the 
lowest seizure incidence.
However, according to Lertxundi et al. [29], some se-
cond-generation antipsychotic drugs (especially clozapine) 
may carry a greater epileptogenic risk than first-generation 
antipsychotics. Olanzapine and quetiapine, both presenting 
significant chemical similarity to clozapine, may carry a higher 
risk than previously thought. It is worth noing that other 
research has not confirmed a greater epileptogenic risk in the 
case of olanzapine and quetiapine compared to first-generation 
antipsychotic drugs.
Clozapine was associated with a higher seizure incidence 
than other second-generation antipsychotic drugs — 3.5% 
— in premarketing studies [16, 30]. Its use in epilepsy is 
restricted to cases of severe psychosis which are refractory 
to other antipsychotic drugs. Very rapid titration and the use 
of high doses of clozapine are the triggers of occurrence of 
seizures which increase by 0.7% for each 100 mg of the drug. 
Up to 300 mg/day, the risk of seizures is comparable to other 
antipsychotic drugs. Between 600 and 900 mg/day, this risk 
reaches 5% [31]. Electroencephalogram abnormalities have 
been reported in 1% for doses of less than 300 mg of clozapine 
a day, in 2.7% for 300–600 mg, and in 4.4% of patients for clo-
zapine doses of 600–900 mg a day [32]. A postmarketing study 
of > 5,000 patients with clozapine indicated a lower incidence 
rate (1.3%), without dose dependency [33].
On the other hand, the positive effect of antipsychotic 
drugs in epilepsy patients has also been described. Antipsy-
chotic drugs may induce beneficial effects on the mental state 
of people with epilepsy [17]. A decreasing effect on seizure 
frequency has been found. For example, the use of aripiprazole, 
melperone and thioridazine at therapeutic doses has been 
reported to reduce the occurrence of seizures in patients with 
epilepsy [18, 19, 34, 50].
Seizures and antipsychotics
According to Ojemann [36] and Gross [37] (based on 
respectively 13 and seven case reports), seizure frequency did 
not increase while treating epilepsy patients with comparatively 
low doses of antipsychotic drugs. After one month of treatment, 
the seizure outcome was markedly better in the antipsychotic 
drug user group than in the control group; only two patients 
with antipsychotic drugs (1.3%) exhibited an increase in se-
izure frequency compared to the baseline, while 13 controls 
(4%) experienced an increase. Patients who are already on an 
antiepileptic drug can be safely treated with a variety of an-
tipsychotic drugs, according to a larger study with a matched 
control group conducted by Okazaki [34]. The seizure outcome 
between first- and second-generation antipsychotic drugs, or 
between mono- and polypharmacy, was not significantly dif-
ferent. However, clozapine was not included in this study. The 
seizure outcome in people with epilepsy improved throughout 
the one-year follow-up period after the administration of an-
tipsychotic drugs for psychiatric conditions [34].
Using antipsychotic drugs in clinical practice 
(Tab. 1)
When starting any drug therapy, some general risk factors 
for seizures have to be considered, including pharmacodynamic 
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Table 1. Antipsychotic drugs in epilepsy — range of clinical features
Group Drug name CYP  
metabolism






































Haloperidol [38] CYP3A4, 
CYP2D6
12–37 h Oral / i.m. Parkinson’s syndrome, 
akathysia, late dyskineses, 
dysthonia, neuroleptic 
malignant syndrome








Olanzapine [39] CYP1A2, 
CYP2D6





– increased drug 
metabolism (with 






Quetiapine [40] CYP3A4 7 h Oral/i.m. Sedation, dizziness, hea-
dache, hyperlipidemia
Risperidone [41] CYP2D6 3h (active 
metaboli-
te – 24 h)




Aripiprazole [42] CYP3A4, 
CYP2D6
75 h Oral/i.m. Anxiety, insomnia, 
extrapyramidal symp-


















Amisulpride [45] Not involved 12 h Oral Parkinson’s syndrome, 
dysthonia, sleep disor-
ders, hyperprolactinemia
Not significant 0.24% 
[28]
and pharmacokinetic interactions, drug selection, drug dosage, 
and patient-related factors. The expected therapeutic drug 
effects may be changed by pharmacokinetic interactions be-
tween antipsychotic drugs and antiepileptic drugs that arise 
from the common metabolism pathway through isoenzymes 
of cytochrome P–450 [5, 14]. 
While choosing antipsychotic drugs, clinicians must 
consider not only lowering the seizure threshold, but 
also other side-effects such as weight gain and sedation, 
especially in concurrent use with antiepileptic drugs (e.g. 
valproate and vigabatrine, carbamazepine or barbiturates). 
Both first- and second-generation antipsychotic drugs 
cause an extrapyramidal syndrome, especially so with first-
-generation drugs. However, compared to first-generation 
antipsychotic drugs, second-generation antipsychotic drugs 
cause more severe side effects in term of weight gain and 
metabolic syndrome [38].
Enzyme-inducing antiepileptic drugs such as phenobarbi-
tal, phenytoin, primidone, and carbamazepine, may increase 
the clearance of psychotropic drugs metabolised in the liver, 
including first-generation antipsychotic drugs (chlorproma-
zine, fluphenazine and haloperidol) and second-generation 
antipsychotic drugs (clozapine, olanzapine, quetiapine, ar-
ipiprazole, and risperidone, with the exception of phenytoin, 
which inhibits risperidone clearance). 
The addition of any of these inducers may be associated 
with a decrease in serum concentration of antipsychotic drugs 
that may evoke a lack of efficacy. On the other hand, the dis-
continuation of enzyme inducers may be bound up with an 
increased serum antipsychotic drug concentration and result 
in adverse drug reactions. Some first-and second-generation 
antipsychotic drugs (respectively haloperidol, loxapine, and 
risperidone, quetiapine) may inhibit the clearance of some 
enzyme-inducing antiepileptic drugs, in particular phenytoin 
411www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Natalia Górska et al., Antipsychotic drugs in epilepsy
and carbamazepine. The pharmacokinetic drug interactions 
assigned to valproate, eslicarbazepine, felbamate, oxcarbaze-
pine, rufinamide and topiramate are generally non-clinically 
relevant in most patients taking antipsychotic drugs, but it is 
possible that in some unusual patients these agents may have 
clinical relevance. It has been reported that valproic acid re-
duces the clearance of antipsychotic drugs [4, 39, 34], inducing 
the metabolism of clozapine [40] and olanzapine [41]. Valpro-
ates seem to have no impact on quetiapine metabolism [42].
In an animal study by Syrek et al., pharmacokinetic interac-
tion between promazine and carbamazepine led to an initial 
increase of promazine concentration, followed by a significant 
decrease over the next few hours [43].
Carbamazepine should be avoided if possible as concurrent 
medication with clozapine due to the risk of suppression of 
the bone marrow induced by the combination of these drugs, 
particularly the risk of agranulocytosis induced by clozapine 
[26]. It is important to emphasise that clozapine itself can 
provoke haematological disorders, and that haematological 
monitoring is needed [31]. Special consideration should be 
given to amisulpride because it does not cause pharmacoki-
netic interactions as it has renal elimination; other advantages 
of this agent are: its very low risk of triggering seizures; no hae-
matotoxic potential; and minimal hepatotoxic potential [28]. 
Conclusion
Antipsychotic drugs can be used both in inpatient and 
outpatient populations, as well as in chronic and acute tre-
atment. Among the first-generation antipsychotic drugs, 
the greatest risk of provoking epileptic seizures is assigned 
to chlorpromazine, while piperazine and piperidine phe-
nothiazines, and butyrophenones, have been reported to be 
associated with a lower risk of seizure induction than other 
first-generation antipsychotic drugs. 
Among second-generation antipsychotic drugs, clozapine 
use carries the highest risk of reducing seizure threshold, while 
risperidone, quetiapine, amisulpride, and aripiprazole seems 
to confer a relatively low such risk. The seizure-risk increase 
is linked to the high blood plasma levels of antipsychotics (e.g. 
due to interactions or in cases of overdose). 
To diminish the risk of seizures, it is important to start with 
a small dose of antipsychotic drugs, to titrate slowly, to monitor 
serum levels of prescribed drugs, and to keep antipsychotic 
drugs at the minimal effective dose. 
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